The biotech-pharma partnership recipe

At no point in the history of drug research have biotech companies and Big Pharma been so closely aligned. Pharma companies have been turning more and more often to biotechs for the kind of cutting-edge technology they need to replenish pipelines. Biotechs routinely build partnership pacts with pharma into their business plans. And the disarray in global markets has made that interrelationship more important than ever.

On October 27 at 2 p.m. EST, FiercePharma and FierceBiotech will present a webinar taking a detailed look at current trends influencing the dealmaking process. We’ve gathered some of the industry’s most experienced players to examine how developers can land the best deals for their companies. The panel includes Ad Rawcliffe, GlaxoSmithKline SVP of Worldwide Business Development and Finance and Anna Protopapas Millennium Takeda SVP of Corporate Development and Strategy, who will discuss key dealmaking strategies. And Geoff Meyerson and Jay Mohr from Locust Walk Partners will present an in-depth survey of what pharma companies are looking for and how developers can best position themselves to take advantage of current trends. If you’re involved in creating new business partnerships, this is one webinar you won’t want to miss. Be sure to register here. – John Carroll

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.